Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 9:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 4,097 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Neuromuscular Disorder Clear all
No Longer Available No phase listed Expanded access

Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for the Treatment of Cerebral Palsy

NCT04029896
View directory record Official record
Conditions
Cerebral Palsy
Interventions
HB-adMSCs
Biological
Lead sponsor
Hope Biosciences Research Foundation
Industry
Eligibility
3 Years and older · Male only
U.S. locations
1
States / cities
Sugar Land, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Oct 16, 2026, 9:59 PM EDT
Recruiting Early Phase 1 Interventional

MDMA-assisted Therapy for Fibromyalgia

NCT06066853
View directory record Official record
Conditions
Fibromyalgia
Interventions
MDMA
Drug
Lead sponsor
Spaulding Rehabilitation Hospital
Other
Eligibility
21 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 16, 2026, 9:59 PM EDT
Completed Phase 2 Interventional Results available

Safety Tolerability and Efficacy Study of Cabaletta to Treat Oculopharyngeal Muscular Dystrophy (OPMD) Patients

NCT02015481
View directory record Official record
Conditions
Oculopharyngeal Muscular Dystrophy
Interventions
Cabaletta
Drug
Lead sponsor
Bioblast Pharma Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Los Angeles, California • Orange, California
Source: ClinicalTrials.gov public record
Updated Oct 17, 2017 · Synced Oct 16, 2026, 9:59 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effects of Increased, Egg-Based Protein Intake on Muscle Composition,

NCT01396915
View directory record Official record
Conditions
Muscle Composition, Sarcopenia, Hypertrophy, Inflammation
Interventions
Dietary Protein Intake
Dietary Supplement
Lead sponsor
Purdue University
Other
Eligibility
55 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 4, 2016 · Synced Oct 16, 2026, 9:59 PM EDT
Recruiting Phase 3 Interventional

The Cancer of the Pancreas Screening-5 CAPS5)Study

NCT02000089
View directory record Official record
Conditions
Pancreas Cancer, Peutz-Jeghers Syndrome (PJS), Gene Mutation, Germline Mutation Carrier, Lynch Syndrome
Interventions
Secretin, MRI, Tumor marker gene test with CA19-9
Drug · Diagnostic Test · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
9,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2029
U.S. locations
9
States / cities
New Haven, Connecticut • Baltimore, Maryland • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Oct 16, 2026, 9:59 PM EDT
Completed No phase listed Observational

Validation of a New Device to Measure Neuromuscular Disease Progression

NCT00606918
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis & Other Neuromuscular Disorders
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 12, 2011 · Synced Oct 16, 2026, 9:59 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas

NCT01140360
View directory record Official record
Conditions
Neurofibromatosis, Neurofibromas
Interventions
Gleevec
Drug
Lead sponsor
Kent Robertson
Other
Eligibility
3 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 16, 2026, 9:59 PM EDT
Active, not recruiting Phase 2 Interventional

Assessment of N-Acetylcysteine as Therapy for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

NCT04542161
View directory record Official record
Conditions
Chronic Fatigue Syndrome, Myalgic Encephalomyelitis
Interventions
NAC 900mg/day, NAC 3600mg/day, NAC 0mg/day (Placebo)
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
21 Years to 60 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 16, 2026, 9:59 PM EDT
Completed No phase listed Observational

Use of Surface Electromyography Biofeedback to Improve Reaching in Children With Cerebral Palsy

NCT00473161
View directory record Official record
Conditions
Cerebral Palsy, Weakness, Hypertonia
Interventions
surface EMG biofeedback
Device
Lead sponsor
University of Southern California
Other
Eligibility
1 Month to 21 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 23, 2014 · Synced Oct 16, 2026, 9:59 PM EDT
Completed Phase 3 Interventional

Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD)

NCT05162768
View directory record Official record
Conditions
Mitochondrial Myopathies, Mitochondrial Pathology, Mitochondrial DNA Mutation, Mitochondrial Diseases, Mitochondrial DNA Deletion, Mitochondrial DNA Depletion, Mitochondrial Metabolism Defect, Mitochondrial Complex I Deficiency
Interventions
Elamipretide, Placebo
Drug
Lead sponsor
Stealth BioTherapeutics Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
9
States / cities
San Diego, California • Atlanta, Georgia • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2025 · Synced Oct 16, 2026, 9:59 PM EDT
Completed Not applicable Interventional

Behavioral Insomnia Therapy for Fibromyalgia

NCT00000397
View directory record Official record
Conditions
Fibromyalgia, Insomnia
Interventions
Behavioral insomnia therapy
Behavioral
Lead sponsor
Duke University
Other
Eligibility
21 Years to 65 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 21, 2014 · Synced Oct 16, 2026, 9:59 PM EDT
Withdrawn Not applicable Interventional

Fatigue in Patients With Amyotrophic Lateral Sclerosis

NCT04468191
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Dysphagia, Dyspnea, Respiration Disorders
Interventions
Experimental expiratory muscle strength training (EMST), Sham expiratory muscle strength training (EMST)
Device
Lead sponsor
Cara Donohue
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 15, 2021 · Synced Oct 16, 2026, 9:59 PM EDT
Completed Phase 3 Interventional

Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS

NCT00021697
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
AVP-923
Drug
Lead sponsor
Avanir Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
17
States / cities
Loma Linda, California • Los Angeles, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Oct 16, 2026, 9:59 PM EDT
Recruiting Phase 2 Interventional

Vasodilator and Exercise Study for DMD (VASO-REx)

NCT06290713
View directory record Official record
Conditions
Duchenne Muscular Dystrophy, Duchenne Disease, Muscular Dystrophy, Muscular Dystrophy in Children, Vasodilation, Exercise, DMD
Interventions
Tadalafil, Placebo, Exercise Training
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
6 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 16, 2026, 9:59 PM EDT
Completed Phase 2 Interventional Results available

A Study for Treatment of Pain in Patients With Diabetic Neuropathy.

NCT00785577
View directory record Official record
Conditions
Diabetic Neuropathy, Painful
Interventions
Placebo, Pregabalin, LY545694 21 mg, LY545694 49 mg, LY545694 105 mg
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
8
States / cities
Greenbrae, California • Tustin, California • DeLand, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated May 31, 2012 · Synced Oct 16, 2026, 9:59 PM EDT
Completed Not applicable Interventional

Effect of Lumbrical Stretching on Carpal Tunnel Syndrome

NCT00803257
View directory record Official record
Conditions
Carpal Tunnel Syndrome
Interventions
Lumbrical splint and Lumbrical exercises
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 13, 2012 · Synced Oct 16, 2026, 9:59 PM EDT
Completed Not applicable Interventional

A Randomized Exercise Trial for Wheelchair Users

NCT00866112
View directory record Official record
Conditions
Spinal Cord Injury, Multiple Sclerosis, Muscular Dystrophy, Cerebral Palsy, Spina Bifida, Amputation, Arthritis, Stroke
Interventions
Educational session to promote physical activity, Minimal contact
Other
Lead sponsor
University of Kansas
Other
Eligibility
18 Years to 65 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Lawrence, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 15, 2012 · Synced Oct 16, 2026, 9:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Transmembrane Electromyography (TM-EMG) for the Assessment of Neuromuscular Function in the Oropharynx

NCT03986671
View directory record Official record
Conditions
Obstructive Sleep Apnea, Amyotrophic Lateral Sclerosis, Muscular Dystrophies, Healthy
Interventions
Transmembrane EMG Oropharynx Probe
Device
Lead sponsor
Powell Mansfield Inc.
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Oct 16, 2026, 9:59 PM EDT
Completed Phase 1Phase 2 Interventional

A Pilot Trial of Rituxan in Refractory Myasthenia Gravis

NCT00619671
View directory record Official record
Conditions
Refractory Myasthenia Gravis
Interventions
Rituximab (Rituxan)
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
2
States / cities
Syracuse, New York • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jan 16, 2013 · Synced Oct 16, 2026, 9:59 PM EDT
Recruiting Not applicable Interventional

Investigating the Effects of Repetitive Transcranial Magnetic Stimulation (rTMS) on the Brain in People With Fibromyalgia

NCT07260864
View directory record Official record
Conditions
Fibromyalgia (FM)
Interventions
rTMS
Other
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 16, 2026, 9:59 PM EDT
Completed Phase 3 Interventional Results available

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)

NCT01545076
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyneuropathy, Polyradiculoneuropathy
Interventions
IgPro20 (low dose), Placebo, IgPro10, IgPro20 (high dose)
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
22
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Oct 16, 2026, 9:59 PM EDT
Recruiting Phase 2 Interventional

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

NCT05735717
View directory record Official record
Conditions
Hematologic Malignancy, Acute Leukemia, Remission, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, AML, TP53, Intrachromosomal Amplification of Chromosome 21, Cytogenetic Abnormality, CNS Leukemia, Minimal Residual Disease, Myelodysplasia, Juvenile Myelomonocytic Leukemia, Somatic Mutation, PTPN11 Gene Mutation, N-RAS Gene Amplification, Neurofibromatosis 1, NF1 Mutation, CBL Gene Mutation, Monosomy 7, Chromosome Abnormality, Fetal Hemoglobin, Lymphoblastic Lymphoma, High Grade Non-Hodgkin's Lymphoma, Adult
Interventions
Fludarabine, Busulfan, Melphalan, Rituximab, Levetiracetam, Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells, Thymoglobulin, Cyclophosphamide
Drug · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 60 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 16, 2026, 9:59 PM EDT
Terminated Phase 1 Interventional

Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.

NCT04586335
View directory record Official record
Conditions
Ovarian Cancer, Breast Cancer, Solid Tumor, Prostate Cancer, Endometrial Cancer
Interventions
CYH33
Drug
Lead sponsor
Haihe Biopharma Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
New Haven, Connecticut • Dallas, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 21, 2024 · Synced Oct 16, 2026, 9:59 PM EDT
Recruiting Phase 1 Interventional

Safety and Efficacy of Autologous Human Schwann Cell (ahSC) Augmentation in Severe Peripheral Nerve Injury (PNI)

NCT05541250
View directory record Official record
Conditions
Peripheral Nerve Injury
Interventions
Autologous Human Schwann Cell
Biological
Lead sponsor
W. Dalton Dietrich
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 16, 2026, 9:59 PM EDT